CN105708915B - Application of Wuwei Huanglian Pills in the Preparation of Medicines for the Treatment of Type Ⅱ Diabetes - Google Patents

Abstract

The invention discloses an application of Wuwei Huanglian Wan in preparing a medicament for treating type II diabetes. The invention overcomes the technical prejudice in the application aspect of the Wuwei Huanglian pills, and discovers through clinical research that the Wuwei Huanglian pills have obvious curative effect on II-type diabetes, particularly the II-type diabetes accompanied with hyperlipidemia, in the aspects of reducing the contents of FBG, CHO, TG and LDL-C and increasing the content of HDL-C, and the effect of the Wuwei Huanglian pills has no obvious difference with the excellent sugar reduction of common medicines.

Description

Application of Wuwei Huanglian Pills in the Preparation of Medicines for the Treatment of Type Ⅱ Diabetes

technical field

The invention belongs to the field of medicine, and particularly relates to the application of Wuwei Huanglian Pills in the preparation of medicines for treating type II diabetes.

Background technique

Type 2 diabetes is a disease characterized by persistent hyperglycemia as the main symptom due to the relative lack of insulin secretion or the decreased sensitivity of human tissues to insulin. Diabetes is an important risk factor for cardiovascular and cerebrovascular diseases. Hyperglycemia and hyperlipidemia often accompany and even promote each other, forming a vicious circle. Therefore, controlling blood sugar and controlling blood lipids to an optimal level can reduce the risk of diabetes and vascular complications.

At present, the drugs for the treatment of type 2 diabetes are mainly divided into two categories: western medicine and Chinese patent medicine. Among them, western medicine can easily cause adverse reactions such as hypoglycemia, gastrointestinal reactions, allergic reactions, and liver and kidney toxicity.

The prescription of Wuwei Huanglian Pill comes from the "Medical Standards of the Ministry of Health of the People's Republic of China·Tibetan Medicine" (Volume 1), which consists of the following medicinal flavors: 300g of Coptis chinensis, 160g of safflower, 200g of myrobalan, 80g of slag taming paste, and 1g of musk. Its functions and indications are: anti-inflammatory, antidiarrheal, and pain relief. For gastroenteritis, chronic diarrhea, abdominal pain, anorexia caused by excessive gallbladder. Through literature and patent searches, there is no report on the drug for the treatment of type 2 diabetes or blood lipids.

SUMMARY OF THE INVENTION

The purpose of the present invention is to provide the application of Wuwei Huanglian Pills in the preparation of medicines for treating type II diabetes.

Terminology Description:

Wuwei Huanglian Pill is the name of the drug recorded in the "Medical Standards of the Ministry of Health of the People's Republic of China · Tibetan Medicine" (Volume 1), the standard number is WS3-BC-0273-95, and it is available in the market.

The present invention is achieved through the following technical solutions:

Application of Wuwei Huanglian Pills in the preparation of medicaments for the treatment of type II diabetes.

Preferably, the application of the present invention especially refers to the application in the preparation of a medicament for the treatment of type II diabetes accompanied by dyslipidemia.

Preferably, for the application of the present invention, the usage and dosage are: 1-2 g at a time, 2-3 times a day.

Preferably, for the application of the present invention, the usage and dosage are: 2 g at a time, 3 times a day.

Preferably, the application of the present invention includes preparing the extract composition according to the formula composition of Wuwei Huanglian Pills, and further preparing any pharmaceutically acceptable preparation.

Beneficial effects:

The original functions of Wuwei Huanglian Pills are: anti-inflammatory, antidiarrheal, and pain relief. It is used for gastroenteritis, chronic diarrhea and abdominal pain, anorexia caused by excessive gallbladder.

Detailed ways

Experimental Example 1. Effect of Wuwei Huanglian Pill on blood glucose and blood lipid levels in experimental type Ⅱ diabetic rats

1. Experimental materials

1.1 Drugs and Reagents

Wuwei Huanglian Pills were provided by Jinhe Tibetan Medicine Co., Ltd., production batch number: 20130501; Myrobalan fine powder, Coptidis fine powder, provided by Jinhe Tibetan Medicine Co., Ltd., batch numbers 20130512 and 20130322, were obtained by ultra-fine grinding of medicinal materials ; Youjiangtang (Glibenclamide Tablets), produced by Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd., approval number: Guoyao Zhunzi H14023991, batch number: 20130420; Streptozotocin (STZ) is a product of Sigma Company; Glucose ( GLU) Kit, Triglyceride (TG) Kit, Total Cholesterol (CHO) Kit, High Density Lipoprotein (HDL-C) Kit, Low Density Lipoprotein (LDL-C) Kit, all are Zhongsheng Products of Beijing Enterprises Biotechnology Co., Ltd.

1.2 Experimental animals

68 male SD rats, mass 175-220 g, were provided by Shandong Lukang Pharmaceutical Co., Ltd., license number: SCXK (Lu) 2013-0001.

2. Experimental method

2.1 Model Replication

All rats were adaptively fed for 1 week before the experiment, and were numbered according to the quality, and 8 rats were randomly selected as the blank group by random number table method; the rest of the rats were referred to "Research and Evaluation of Traditional Chinese Medicine Pharmacodynamics [M]. Shaanxi: Shaanxi Science and Technology Publishing. Society, 2005" method to give a one-time intraperitoneal injection of STZ solution (0.1mol/L sodium citrate buffer, pH 4.2) at a dose of 65mg/kg, measure fasting blood glucose after 2 weeks (after fasting for 12h), randomly select blood glucose 40 rats with a value of ≥16.67mmol/L were fed a high-calorie diet (22% fat, 52% sucrose, 18% protein and a small amount of mixed salt, vitamins and cellulose, calorie 20J/g) for 8 consecutive weeks , made a type Ⅱ experimental diabetes and obesity rat model.

2.2 Grouping and treatment

The above-mentioned model rats were randomly divided into 5 groups according to their body weight, with 8 rats in each group, namely model group, positive control group, myrobalan group, Coptis chinensis group, and Wuwei Huanglian group. On the 2nd day, gavage was started, the blank group and model group were given equal volume of normal saline, and the positive control group, myrobalan group, Huanglian group, and Wuweihuanglian group were given Youjiangsu 1.65 mg/(kg·d), myrobalan fine powder, respectively. 0.17g/(kg·d), Coptis Coptidis fine powder 0.26g/(kg·d), Wuwei Huanglian Pills 0.63g/(kg·d), once a day, for 14 days. All animals were fed with common chow after the drug was started.

2.3 Specimen collection and processing

Before the last administration, the animals were fasted for 12 hours, anesthetized by intraperitoneal injection of 40 mL/kg of 2% sodium pentobarbital sodium saline solution, and blood was collected from the abdominal femoral vein to determine FBG, TG, CHO, HDL-C, and LDL-C according to the kit instructions . SPSS17.0 statistical software was used for processing, and t test was used for comparison between groups.

3 Results: see Table 1.

单位：mmol/L，n＝8)Table 1 Effects on blood glucose and blood lipids in experimental type Ⅱ diabetic rats (

Unit: mmol/L, n=8)

Note: Compared with control group: ^## P<0.01; compared with model group: ^* P<0.05; ^** P<0.01; compared with Wuwei Huanglian group: ^△ P<0.05, ^△△ P<0.01.

4 Conclusion

The results showed that the contents of FBG, CHO, TG and LDL-C in the model group were significantly higher than those in the normal group, and the contents of HDL-C were significantly lower than those in the normal group. ), indicating that the model was successfully replicated. After 14 days of drug treatment, the contents of FBG, CHO, TG and LDL-C in the positive control group and Wuwei Huanglian group were significantly lower than those in the model group, and the content of HDL-C was significantly higher than that in the model group. Compared with the model group, the differences were statistically significant (P< 0.01 or P<0.05), indicating that Wuwei Huanglian Pills can significantly reduce the fasting blood glucose of STZ and obese model rats CHO, TG and LDL-C content, and increase HDL-C content. Compared with the model group, the FBG, CHO and TG of the Myrobalan and Coptidis groups were decreased, and the difference was statistically significant (P<0.05), but the difference was not statistically significant (P>0.05). The effect of CHO and TG had no significant effect on the content of LDL-C and HDL-C. Compared with the Myrobalan group and the Coptidis group, the differences in FBG and TG were statistically significant (P<0.05), indicating that the Wuwei Huanglian group had a statistically significant difference (P<0.05). Compared with Myrobalan and Coptidis, the effect of lowering fasting blood sugar and triglyceride was better; there was no significant difference between the positive control group and Wuwei Coptidis group (P>0.05).

The following embodiments can all achieve the effects of the above experimental examples. The Wuwei Huanglian Pills used in the examples are products produced by Qinghai Jinhe Tibetan Medicine Pharmaceutical Co., Ltd.

Example 1. Application of Wuwei Huanglian Pills in the preparation of medicines for the treatment of type Ⅱ diabetes

Its usage and dosage are: 2g once, 3 times a day.

Example 2. Application of Wuwei Huanglian Pills in the preparation of medicines for the treatment of type II diabetes with dyslipidemia.

Its usage and dosage are: 2g once, 3 times a day.

Example 3. Application of Wuwei Huanglian Pills in the preparation of medicaments for the treatment of type II diabetes.

Its usage and dosage are: 1g at a time, 2 times a day.

Example 4. Application of Wuwei Huanglian Pills in the preparation of medicaments for the treatment of type II diabetes.

Its usage and dosage are: 1g at a time, 3 times a day.

Example 5. Application of Wuwei Huanglian Pills in the preparation of medicines for the treatment of type II diabetes with dyslipidemia.

Its usage and dosage are: 2g once, 2 times a day.

Example 6. Application of Wuwei Huanglian Pills in the preparation of medicines for the treatment of type II diabetes with dyslipidemia.

Its usage and dosage are: 1g at a time, 3 times a day.

Claims (4)

1. Application of Wuwei Huanglian Pills in the preparation of medicines for the treatment of type II diabetes mellitus, which is accompanied by dyslipidemia. 2. The application according to claim 1, characterized in that its usage and dosage are: 1-2 g at a time, 2-3 times a day. 3. according to the application of claim 2, it is characterized in that, its usage and dosage is: once 2g, 3 times a day. 4. The application according to claim 1, characterized in that, the medicines include Wuwei Huanglian Pills and any pharmaceutically acceptable preparations further prepared after preparing the extract composition according to the formula composition thereof.